Litcius/Paper detail

Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial

Nitesh V. Patel, Tamika Wong, Sherese Fralin, Mona Li, Amy McKeown, Deborah Gruber, Randy S. D’Amico, Athos Patsalides, Apostolos John Tsiouris, Dimitre G. Stefanov, Oscar Falcón Flores, Avraham Zlochower, Christopher G. Filippi, Rafael Ortiz, David J. Langer, John A. Boockvar

2021Journal of Neuro-Oncology29 citationsDOI

Topics & Concepts

BevacizumabMedicineInternal medicineConfidence intervalIsocitrate dehydrogenasePhases of clinical researchGastroenterologySurgeryUrologyOncologyClinical trialChemotherapyEnzymeBiochemistryChemistryGlioma Diagnosis and TreatmentBrain Metastases and TreatmentAngiogenesis and VEGF in Cancer
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial | Litcius